Ken Griffin Mesoblast LTD Transaction History

Citadel Advisors LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.0 - $1.39 $5,337 - $7,418	5,337 New	5,337 $5,000
Q2 2023 Aug 14, 2023	SELL	$2.95 - $4.44 $2,301 - $3,463	-780 Reduced 1.37%	56,286 $220,000
Q1 2023 May 15, 2023	SELL	$2.94 - $4.18 $236,567 - $336,343	-80,465 Reduced 58.51%	57,066 $187,000
Q4 2022 Feb 14, 2023	BUY	$2.73 - $3.7 $375,459 - $508,864	137,531 New	137,531 $400,000
Q4 2021 Feb 14, 2022	SELL	$4.17 - $7.09 $33,943 - $57,712	-8,140 Reduced 16.37%	41,598 $199,000
Q3 2021 Nov 15, 2021	BUY	$5.87 - $7.85 $35,601 - $47,610	6,065 Added 13.89%	49,738 $299,000
Q2 2021 Aug 16, 2021	BUY	$6.69 - $9.0 $45,284 - $60,921	6,769 Added 18.34%	43,673 $326,000
Q1 2021 May 17, 2021	SELL	$8.26 - $11.4 $70,763 - $97,663	-8,567 Reduced 18.84%	36,904 $305,000
Q3 2020 Nov 16, 2020	BUY	$11.33 - $19.81 $105,233 - $183,995	9,288 Added 25.67%	45,471 $844,000
Q2 2020 Aug 14, 2020	BUY	$4.2 - $15.45 $76,876 - $282,796	18,304 Added 102.38%	36,183 $412,000
Q1 2020 May 15, 2020	BUY	$3.38 - $10.63 $60,431 - $190,053	17,879 New	17,879 $78,000
Q4 2019 Feb 14, 2020	SELL	$5.74 - $7.42 $67,221 - $86,895	-11,711 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$4.68 - $7.42 $68,281 - $108,257	-14,590 Reduced 55.47%	11,711 $81,000
Q3 2018 Nov 13, 2018	BUY	$5.75 - $8.16 $151,230 - $214,616	26,301 New	26,301 $0

151K

Ticker MESO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 147,316,000
Market Cap $1.2B
Description
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.